Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus maintenance therapy in metastatic soft-tissue or bone sarcoma
2007-003462-18Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2007
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) and bone cancer comparing Ridaforolimus maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Nov 2007; status: completed.
02
Drugs
ridaforolimus
03
Conditions
soft tissue sarcoma (STS)bone cancer
Beyond the preview
Go deeper on 2007-003462-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003462-18.